Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

2NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSSeptember 30, 2010December 31, 2009 (1)Current assets:Cash and cash equivalents

$
2,906$
49,597Short-term investments

290,396346,614Accounts receivable

5,5534,801Inventory

11,4606,471Other current assets

6,1196,183Total current assets

$
326,434$
413,666Property and equipment, net

97,68678,263Goodwill

76,50176,501Other assets

1,8557,088Total  assets

$
502,476$
575,518LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
4,403$
3,066Accrued compensation

10,55210,052Accrued expenses

12,3524,354Accrued clinical trial expenses

12,75914,167Deferred revenue, current portion

40,232115,563Interest payable

581,805Other current liabilities

4,4764,009Total current liabilities

$
84,832$
53,016Convertible subordinated notes

214,955214,955Capital lease obligations

17,40218,800Deferred revenue

69,03376,809Deferred gain

4,3715,027Other long-term liabilities

4,9364,544Total liabilities

$
395,529$
473,151Commitments and contingenciesStockholders' equity:Preferred stock

$
-$
-Common stock

99Capital in excess of par value

1,347,8001,327,942Accumulated other comprehensive income

1,1051,025Accumulated deficit

(1,241,967)(1,226,609)Total stockholders' equity

$
,947$
2,367Total liabilities and stockholders' equity

$
502,476$
575,518(1) The consolidated balance sheet at December 31, 2009 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Drugs - Global Strategic Business Report" report to their ... for Human Growth Hormone Drugs in US$ Million by the ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
(Date:8/19/2014)... Aug. 19, 2014  Stryker Corporation,s Orthopaedics Division, the Official ... is bringing its message of joint health to golf fans ... this week at The Barclays.  The company,s fan destination ... Spectator Village near the 17 th fairway at the ... on Thursday, August 21 st .    At ...
Breaking Medicine Technology:Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5
... 31, 2011 Boston Scientific Corporation (NYSE: ... Food and Drug Administration (FDA) has approved its ... and delivery of diagnostic, embolic and therapeutic materials ... be used by interventional radiologists for minimally invasive ...
... Endologix, Inc. (Nasdaq: ELGX ), ... announced today the publication of favorable clinical results ... of abdominal aortic aneurysm (EVAR).  The peer-reviewed article ... trial, with successful aneurysm exclusion in all patients, ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 2Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 3Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 4Endologix Announces Favorable Clinical Results for Nellix Technology 2Endologix Announces Favorable Clinical Results for Nellix Technology 3
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... San Mateo, CA (PRWEB) August 20, 2014 ... their newest product—the Really Little Green Pouch —to ... easier to feed babies and toddlers homemade foods. ... says Little Green Pouch co-founder Maggie Crawford. She ... their kids, to limit exposure to things like pesticides ...
(Date:8/20/2014)... 2014 "I decided that there needed ... an optimal manner without the hassles associated with using ... , The patent-pending DR. GATES ORAL-HYGIENE TOOL provides an ... It promotes good oral hygiene and fresh breath, and ... Convenient, compact, affordable, eco-friendly and easy to use, the ...
(Date:8/20/2014)... been chosen by Plymouth University to be an official ... 2009 to raise awareness of, and funding for, scientific ... tumour patients. , A range of events and activities ... charity, and members of staff and students, as well ... fundraise and volunteer. The involvement of the wider community ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... available since the middle of 2011 as a treatment ... early benefit assessment pursuant to the "Act on the ... German Institute for Quality and Efficiency in Health Care ... added benefit in comparison with the previous standard therapy. ...
... study, initiated by the Swiss researchers and published in ... in the brain. Anxiety disorders constitute a complex ... Patients suffering from such disorders fear certain situations or ... the real danger they present. The amygdala, a ...
... -- The presence of circulating tumor cells in the blood ... have just been diagnosed with inflammatory breast cancer, according to ... research shows that these stray tumor cells may signal that ... even before imaging reveals any metastases. The results will ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, Dec. ... especially starches, may boost the risk of breast cancer ... public health doctoral student at the University of California, ... carbohydrates, particularly starchy foods such as potatoes, that breast ...
... Biology (FASEB) is pleased to announce the addition of ... the Society for Pediatric Research, which will bring the ... very dynamic groups representing extremely important areas of research, ... said FASEB President Joseph C. LaManna, PhD. "We welcome ...
... a University of Notre Dame researcher, is one of the coauthors ... scientists in academia and industry that calls for strong steps to ... bacteria. The group issued a priority list of steps that need ... The paper is an outgrowth of a meeting the group ...
Cached Medicine News:Health News:Boceprevir: Indication of added benefit for specific patients 2Health News:Boceprevir: Indication of added benefit for specific patients 3Health News:The cortex plays an essential part in emotional learning 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 3Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 2Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 3Health News:New paper calls for strong steps to tackle antibiotic resistance 2
... multifunction plate reader that offers four different ... time-resolved fluorescence, high-perfomance luminescence and absorbance. The ... that deliver reagent at the point of ... can be performed easily and allowing the ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
... VICTOR2 multilabel counter with ... stacker and robot loading ... density time-resolved fluorescence, luminescence ... of the instrument is ...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
Medicine Products: